Ensituximab is a chimeric monoclonal IgG1 antibody that targets a glycosylated variant of MUC5AC with specificity to colorectal and pancreatic cancer. Ensituximab was well tolerated and demonstrated modest antitumor activity in patients with heavily pretreated refractory colorectal cancer.